Cell Innovation Partners
Overview
Cell Innovation Partners is a Japanese venture capital firm specializing in biotechnology investments. Established in 2014, the firm focuses on supporting the development of next-generation biotechnology businesses, particularly in the fields of regenerative medicine and cell therapy. The firm aims to bridge the gap between academic research and commercial application by providing funding and strategic support to emerging biotech companies. The firm's investment strategy encompasses a wide range of stages, from seed funding to pre-IPO investments, reflecting its commitment to nurturing companies throughout their growth trajectories. Cell Innovation Partners has a global investment approach, with a geographical focus that includes Japan, the United States, Europe, China, South Korea, India, Australia, Canada, Brazil, Mexico, Russia, South Africa, Singapore, Israel, the United Kingdom, France, Germany, Italy, Spain, the Netherlands, and Sweden. This diverse focus enables the firm to tap into a broad spectrum of innovative biotech opportunities worldwide. Cell Innovation Partners has a diverse portfolio of companies across various sectors within the biotechnology industry. Their investments span areas such as regenerative medicine, cell therapy, stem cell research, gene therapy, immunotherapy, oncology, neurology, cardiology, orthopedics, dermatology, ophthalmology, pulmonology, gastroenterology, endocrinology, and infectious diseases. This extensive portfolio underscores the firm's dedication to advancing medical treatments and technologies that address a wide array of health challenges. The firm's investment philosophy centers on identifying and supporting innovative biotech ventures with the potential to make significant impacts in the healthcare sector. By providing both financial resources and strategic guidance, Cell Innovation Partners aims to accelerate the commercialization of groundbreaking medical technologies, thereby contributing to the advancement of global healthcare solutions. Cell Innovation Partners is a Japanese venture capital firm specializing in biotechnology investments. Established in 2014, the firm focuses on supporting the development of next-generation biotechnology businesses, particularly in the fields of regenerative medicine and cell therapy. The firm aims to bridge the gap between academic research and commercial application by providing funding and strategic support to emerging biotech companies. The firm's investment strategy encompasses a wide range of stages, from seed funding to pre-IPO investments, reflecting its commitment to nurturing companies throughout their growth trajectories. Cell Innovation Partners has a global investment approach, with a geographical focus that includes Japan, the United States, Europe, China, South Korea, India, Australia, Canada, Brazil, Mexico, Russia, South Africa, Singapore, Israel, the United Kingdom, France, Germany, Italy, Spain, the Netherlands, and Sweden. This diverse focus enables the firm to tap into a broad spectrum of innovative biotech opportunities worldwide. Cell Innovation Partners has a diverse portfolio of companies across various sectors within the biotechnology industry. Their investments span areas such as regenerative medicine, cell therapy, stem cell research, gene therapy, immunotherapy, oncology, neurology, cardiology, orthopedics, dermatology, ophthalmology, pulmonology, gastroenterology, endocrinology, and infectious diseases. This extensive portfolio underscores the firm's dedication to advancing medical treatments and technologies that address a wide array of health challenges. The firm's investment philosophy centers on identifying and supporting innovative biotech ventures with the potential to make significant impacts in the healthcare sector. By providing both financial resources and strategic guidance, Cell Innovation Partners aims to accelerate the commercialization of groundbreaking medical technologies, thereby contributing t
Investment Focus
- Innovative biotechnology ventures
- Strong management teams
- Scalable business models
- Potential for significant impact in healthcare
- Alignment with firm's investment focus areas
Portfolio Companies
Reach Cell Innovation Partners directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Cell Innovation Partners
What sectors does Cell Innovation Partners invest in?
Cell Innovation Partners invests in Healthcare, Pharmaceuticals, Medical Devices, Diagnostics, Biotechnology and Regenerative Medicine, and is based in Kanagawa, Japan. Cell Innovation Partners is listed as a venture capital in the ConnectSafely investor database.
What stage does Cell Innovation Partners invest at?
Cell Innovation Partners backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 1M - 50M.
Which regions does Cell Innovation Partners invest in?
Cell Innovation Partners invests across United States, United Kingdom, Canada, Germany, Japan and Australia.
What companies has Cell Innovation Partners invested in?
Cell Innovation Partners's portfolio includes CellSeed Inc., CellFiber Inc., CellGenTech, Inc., CellTech Accelerator, CellTech Innovation Venture Studio Co., Ltd., CellTech Innovation Co., Ltd. and CellTech.
Last updated · Source: ConnectSafely investor database
